Determination of the optimal therapeutic protocols in cancer immunotherapy

Mathematical Biosciences

Volumn 209, Issue 1, 2007, Pages 1-13

  Cappuccio, Antonio ^a   Castiglione, Filippo ^a   Piccoli, Benedetto ^a  

^a CNR   (Italy)

Author keywords

Cancer; Drug holidays; Immunotherapy; Optimization; Protocol design

Indexed keywords

DRUG PRODUCTS; IMMUNOLOGY; ONCOLOGY; OPTIMIZATION; TOXICITY; TUMORS;

DRUG HOLIDAYS; IMMUNOTHERAPY; PROTOCOL DESIGN;

DRUG THERAPY;

CANCER VACCINE; INTERLEUKIN 2;

ALGORITHM; CANCER; CHEMOTHERAPY; DRUG; IMMUNE RESPONSE; OPTIMIZATION; TOXICITY; TUMOR;

ALGORITHM; ANTIGENICITY; ARTICLE; BLOOD CELL COUNT; CANCER; CANCER GROWTH; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; EFFECTOR CELL; FLUID RETENTION; HUMAN; IMMUNE SYSTEM; MATHEMATICAL MODEL; NAUSEA; SIDE EFFECT; SIMULATION; TUMOR RECURRENCE; VOMITING;

ALGORITHMS; COMPUTER SIMULATION; DRUG ADMINISTRATION SCHEDULE; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; MODELS, IMMUNOLOGICAL; NEOPLASMS;

EID: 34547794152     PISSN: 00255564     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mbs.2007.02.009     Document Type: Article

References (13)

1. Castiglione F., and Piccoli B. Optimal control in a model of dendritic cell transfection cancer immunotherapy. Bull. Math. Biol. 68 (2006) 255-274
2. Piccoli B., and Castiglione F. Optimal vaccine scheduling in cancer immunotherapy. Physica A 370 2 (2007) 672-680
3. Kirschner D., and Panetta J.C. Modeling immunotherapy of tumor-immune interaction. J. Math. Biol. 37 (1998) 235
4. Ben-Efraim S. Cancer immunotherapy: hopes and pitfalls: a review. Anticancer Res. 16 5B (1996) 3235
5. Martin R.B. Optimal control drug scheduling of cancer chemotherapy. Automatica 28 (1992) 1113
6. Burden T., Ernstberger J., and Fister K.R. Optimal control applied to immunotherapy. Disc. Cont. Dyn. Sys. B. 4 1 (2004) 135
7. Swierniak A., Ledzewicz U., and Schattler H. Optimal control for a class of compartmental models in cancer chemotherapy. Int. J. Appl. Math. Comp. Sci. 13 3 (2003) 357
8. In: Preziosi L. (Ed). Cancer Modeling and Simulation (2003), Chapman and Hall/CRC Press (UK), London (June 26)
9. Blumberg N., Chuang-Stein C., and Heal J.M. The relationship of blood transfusion, tumor staging, and cancer recurrence. Transfusion 30 4 (1990) 291
10. Hirao Y., Okajima E., Ozono S., Samma S., Sasaki K., Hiramatsu T., Babaya K., Watanabe S., and Maruyama Y. A prospective randomized study of prophylaxis of tumor recurrence following transurethral resection of superficial bladder cancer-intravesical thio-TEPA versus oral UFT. Cancer Chemother Pharmacol 30 (1992) S26
11. Gatti R.A., Robinson W.A., Deinard A.S., Nesbit M., McCullough J.J., Ballow M., and Good R.A. Cyclic leukocytosis in chronic myelogenous leukemia: New perspectives on pathogenesis and therapy. Blood 41 6 (1973) 771
12. Kennedy B.J. Cyclic leukocyte oscillations in chronic mylegenous leukemia during hydroxyurea therapy. Blood 35 6 (1970) 751
13. Castiglione, Piccoli, Work in Progress.